KHCM
LYEL icon

Kettle Hill Capital Management’s Lyell Immunopharma LYEL Stock Holding History

Kettle Hill Capital Management’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-7,920
Closed -$1.16M – 66
2022
Q3 		$1.16M Buy
7,920
+35
+0.4% +$4.74K 0.27% 47
2022
Q2 		$1.03M Buy
+7,885
New +$806K 0.26% 44

Other funds holding LYEL

MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Kettle Hill Capital Management's LYEL Position: Q4 2022 in Review

Kettle Hill Capital Management sold out of Lyell Immunopharma (LYEL) in Q4 2022, closing a stake of 7,920 shares — an estimated $1.16M sold.

Kettle Hill Capital Management first reported a position in LYEL in Q2 2022 and held it in 2 quarters. The position peaked at $1.16M in Q3 2022. 92 funds tracked by Wall St. Rank hold LYEL as of Q4 2022.

  • Kettle Hill Capital Management reported no remaining Lyell Immunopharma position as of Q4 2022 after selling out during the quarter.
  • Kettle Hill Capital Management sold 7,920 Lyell Immunopharma shares in Q4 2022, an estimated $1.16M.
  • Kettle Hill Capital Management first reported a position in Lyell Immunopharma in Q2 2022 and held it in 2 quarters.
  • Kettle Hill Capital Management's Lyell Immunopharma position peaked at $1.16M in Q3 2022.
  • 92 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q4 2022.

Based on Kettle Hill Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.